Try Alerts Free   |   Login
Health Care › Services-Commercial Physical And Biological Research

MEDP Price Correlated With Financials For Medpace Holdings

Free historical financial statements for Medpace Holdings Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 18 quarters since 2018. Compare with MEDP stock chart to see long term trends.

MEDP Stock Compared to Quarterly

MEDP Income Statement

Revenue, Net:351207000
Revenue Per Share:10.8087
Selling, General & Admin Expense:33215000
Total Operating Expenses:290971000
Operating Income:61999000
Income Taxes:12639000
Net Income:49360000
Earnings Per Share, Basic:1.52
Shares Outstanding, Basic Avg:32493000

MEDP Cash Flow

Operating Activities Net Income:
Net Cash from Operations:96619000
Net Cash from Operations Per Share:2.9735
Repurchases/Buybacks Common Stock:374717000
Net Cash from Financing Activities:-123463000
Property, Plant & Equipment Purchases:11200000
Net Cash from Investing Activities:-11127000
Net Change in Cash & Equivalents:-40292000

MEDP Balance Sheet

Cash and Cash Equivalents:42551000
Total Current Assets:328887000
Property, Plant & Equipment, Net:103538000
Total Assets:1315453000
Accounts Payable:28800000
Total Short-Term Liabilities:878959000
Total Liabilities:1032201000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Medpace Investors, LLC   10% Owner
8,330 sh at $145
$1,207,850
Buy
Troendle August J.   CEO
8,330 sh at $145
$1,207,850
Buy
Medpace Investors, LLC   10% Owner
22,290 sh at $145
$3,222,911
Buy
Troendle August J.   CEO
22,290 sh at $145
$3,222,911
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock Inc.
3,792,694 sh
35,121 sh
1%
$620,448
-$197,349
Vanguard Group Inc
3,128,221 sh
-40,998 sh
-1%
$511,746
-$178,004
Wasatch Advisors Inc
2,728,392 sh
294,103 sh
12%
$446,338
-$83,461
Invesco Ltd.
894,024 sh
-91,906 sh
-9%
$146,252
-$68,326
Boston Trust Walden Corp
674,994 sh
186,518 sh
38%
$110,423
$4,111
Dimensional Fund Advisors LP
656,864 sh
9,881 sh
2%
$107,456
-$33,354
Geode Capital Management, LLC
544,358 sh
7,605 sh
1%
$89,051
-$27,767
Fuller & Thaler Asset Management, Inc.
494,491 sh
-956 sh
0%
$80,894
-$26,935
Northern Trust Corp
406,601 sh
-20,494 sh
-5%
$66,515
-$26,438
Renaissance Technologies LLC
380,088 sh
-14,800 sh
-4%
$62,179
-$23,764
Riverbridge Partners LLC
334,179 sh
30,158 sh
10%
$54,668
-$11,499
GW&K Investment Management, LLC
330,146 sh
-4,823 sh
-1%
$54,009
-$18,894
GW&K Investment Management, LLC
330,146 sh
-4,823 sh
-1%
$54,009
-$18,894
FMR LLC
328,585 sh
21,449 sh
7%
$53,754
-$13,091
Ranger Investment Management, L.P.
316,902 sh
8,200 sh
3%
$51,842
-$15,344
Bank Of New York Mellon Corp
311,918 sh
-9,601 sh
-3%
$51,026
-$18,950
Fisher Asset Management, LLC
304,913 sh
-6,400 sh
-2%
$49,881
-$17,873
Charles Schwab Investment Management Inc
285,733 sh
-1,100 sh
0%
$46,744
-$15,683
Eagle Asset Management Inc
278,734 sh
25,053 sh
10%
$45,598
-$9,978
Epoch Investment Partners, Inc.
278,463 sh
33,056 sh
13%
$45,553
-$7,857
COMPANY PROFILE
1. BASIS OF PRESENTATION Description of Business Medpace Holdings, Inc. together with its subsidiaries, (“Medpace” or the “Company”), a Delaware corporation, is a global provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia. Share Repurchases In 2018, the Board of Directors approved a stock repurchase program which has been amended several times to increase the aggregate amount of the stock repurchase authorization. In the first quarter of 2020, the Board of Directors approved an increase in the stock repurchase authorization by $ 50.0 million. In the fourth quarter of 2020, the Board approved the stock repurchase authorization up to $ 150.0 million. In the second quarter of 2021, the Board approved an increase of $ 150.0 million to the stock repurchase program bringing the total repurchase authorization up to $ 300.0 million. For the year ended December 31, 2021, the Company repurchased 377,783 shares for $ 62.1 million. For the year ended December 31, 2020, the Company repurchased 1,183,095 shares for $ 98.3 million. As of December 31, 2021, the Company has remaining authorization of $ 190.5 million remaining under the repurchases program. As of February 10, 2022 the Company's Board of Directors approved an increase of $ 300 million to the Company's stock repurchase program. Repurchases under the share repurchase program are executed in the open market or negotiated transactions under trading plans established pursuant to Rule 10b5-1. The Company constructively retired the repurchased shares associated with these approved share repurchase programs, with all amounts paid in excess of par value reflected within Retained earnings in the Company’s consolidated balance sheets. The repurchase program may be suspended or discontinued at any time without notice.

Data imported from Medpace Holdings Inc SEC filings. Check original filings before making any investment decision.